Transforming growth factor beta 1 genotype and p16 as prognostic factors in head and neck squamous cell carcinoma

Acta Oto-Laryngologica

Volumn 132, Issue 9, 2012, Pages 1006-1012

  Lundberg, Marie ^a,b   Leivo, Ilmo ^b,c   Saarilahti, Kauko ^a   Mäkitie, Antti A ^a,b   Mattila, Petri S ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cisplatin; Epidermal growth factor receptor; Human papilloma virus; Radiotherapy

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ADULT; AGED; ARTICLE; BLOOD; CANCER CHEMOTHERAPY; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84865341515     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016489.2012.678944     Document Type: Article

References (20)

1. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010;15:994-1001.
2. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20. (Pubitemid 30365531)
3. Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009;4:49-70.
4. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35.
5. Marur S, D'Souza G, Westra WH, Forastiere AA. HPVassociated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781-9.
6. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007;121: 2465-72. (Pubitemid 350022416)
7. Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH. Zhang Q, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010; 34:1088-96.
8. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26: 3128-37.
9. Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120:1731-8. (Pubitemid 46399359)
10. Lundberg M, Pajusto M, Koskinen WJ, Makitie AA, Aaltonen LM, Mattila PS. Association between transforming growth factor beta1 genetic polymorphism and response to chemoradiotherapy in head and neck squamous cell cancer. Head Neck 2009;31:664-72.
11. Lundberg M, Saarilahti K, Makitie AA, Mattila PS. TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis. Oral Oncol 2010;46:369-72.
12. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, et al. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-15. (Pubitemid 36605203)
13. Guan X, Sturgis EM, Lei D, Liu Z, Dahlstrom KR, Wei Q, et al. Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer. Clin Cancer Res 2010;16:1416-22.
14. Peralta-Zaragoza O, Bermudez-Morales V, Gutierrez- Xicotencatl L, Alcocer-Gonzalez J, Recillas-Targa F, Madrid-Marina V. E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor beta1 promoter throughout Sp1 recognition sequence. Viral Immunol 2006;19:468-80. (Pubitemid 44735059)
15. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73. (Pubitemid 46349843)
16. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15. (Pubitemid 351636299)
17. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 2008;26:2871-5.
18. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26:2839-45.
19. Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, et al. Blockade of TGF-b signaling by the TGFßR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011;71:7155-67.
20. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, et al. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol 2008;70:752-9.